Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Investors' Conference, June 25-27, 2025
46 slides from Zydus Lifesciences's conference presentation, Jun 24, 2025
Slide 1: Cover letter to stock exchanges
June 24, 2025 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Mumbai-400 001 Listing Department Code: Zyduslife NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, C/1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai-400 051 Re.: Investor Presentation for Investor Confer
Slide 2: Zydus Lifesciences Limited Investor Presentation June 2025
Zydus Lifesciences Limited Investor Presentation June 2025 1
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general
Slide 4: Zydus at a Glance
Zydus at a Glance A Leading Lifesciences Player With a Global Footprint Aptly Supported by API Alliances IM ~ US$ 2.75 bn 10% 2% 1% Revenues1 in India Geography 38 FY25 38% Manufacturing facilities FY25 Formulations 26% Sales Consumer Wellness 12% US$ 835 mn Rs. 225.7 bn EBITDA1 in FY25 (30.4% margi
Slide 5: Innovation Updates
Innovation Updates
Slide 6: Innovation at the Core: Creating an ecosystem focused on patient-centricity
Innovation at the Core: Creating an ecosystem focused on patient-centricity Orphan Disease & Specialty Portfolio through 505(b)(2) NCEs Portfolio of nine 505(b)(2) programs; Saroglitazar – World’s first approved therapy for 3 of them approved and launched MASH Biosimilars Presence in liquid orals sp
Slide 7: US Generics Pipeline: Building sustainability through differentiation
US Generics Pipeline: Building sustainability through differentiation Pivoting towards differentiated, high value opportunities Leveraging the licensing strategy for technically complex products with large opportunity size From To Market NCE-1, First-to-file Focus • Volume-centric • Value centric, d
Slide 8: India Portfolio: Value creation through new launches
India Portfolio: Value creation through new launches keeping innovation and affordability at core First-in-India, Day-1 launches and next generation Drug Delivery Multiple initiatives being undertaken towards ensuring access platforms will be one of the key growth drivers and affordability to patien
Slide 9: NCEs and NBEs: Highlights and focus therapy areas
NCEs and NBEs: Highlights and focus therapy Areas NCEs Pipeline Novel Approved Products Drug Lead Pre- Project Target Indication IND Phase I Phase II Phase III NDA Launch Disc. Optim. clinical PBC & PPAR- α:γ Saroglitazar MASH MASH PBC agonist (for US) Sickle Cell First NCE Approved/ Launched In Ind
Slide 10: NCE – Saroglitazar: Addressing unmet needs in PBC and MASH
NCE – Saroglitazar : Leveraging strengths and experience in liver diseases to address unmet medical needs in PBC and MASH indications globally Primary Biliary Cholangitis (PBC) • A rare, progressive auto-immune disease which affects women, with 1 in 1000 women over 40 years of age being affected. Sa
Slide 11: NCE – Desidustat: First novel oral alternative to injectable ESAs
NCE – Desidustat: First novel oral alternative to injectable ESAs approved in India for anemia in CKD patients ~17% Prevalence of CKD patients in INDIA >120 Mn People are estimated to be living with CKD in CHINA • Provided relief to over 65000 patients • Granted an exclusive license to the molecule
Slide 12: NCE – Usnoflast: First-in-class NLRP3 inhibitor
NCE – Usnoflast: First-in-class small molecule NLRP3 inhibitor aimed at addressing unmet needs in Neurodegenerative and Autoimmune Diseases Amyotrophic Lateral Sclerosis (ALS) Ulcerative Colitis (UC) • A progressive, fatal neurodegenerative disease which affects nerve cells controlling voluntary mus
Slide 13: Biosimilars: Amongst largest players in India
Biosimilars: Amongst largest players in India; increasing reach in Emerging markets Largest biosimilar portfolio and pipeline Domestic market Recent Approvals In India, Zydus is #1 player in 14 biosimilars launched/ approved Oncology Nivolumab (Approved), Pertuzumab, World’s first biosimilar Oncolog
Slide 14: Vaccines: End-to-end development expertise
Vaccines: End-to-end development expertise 20+ Vaccine innovation comes from an R&D center focused on developing different types of vaccines Vaccine products in portfolio • Vaccine discovery – viral, bacterial, recombinant and others Multiple types • Process and analytical development Of offerings •
Slide 15: Vaccines: Comprehensive portfolio with platform diversity
Vaccines: Comprehensive portfolio with platform diversity Indian company to Indian company to Company globally ✓ WHO PQ for In the world to have indigenously indigenously with an approved 1st developed H1N1 2nd develop Typhoid 2nd develop and launch 1st pDNA vaccine for Typhoid conjugate vaccine Con
Slide 16: Zydus' Innovation Engine is fueled by Centers of Excellence
Zydus’ Innovation Engine is fueled by Centers of Excellence R&D Investment US$ mn R&D Cost % of Revenues 7.8 6.9 8.0 155 7.2 6.7 10 219 NCE / NBE Research 135 8 Generic Development - Moraiya 6 158 154 151 115 140 4 95 2 75 0 FY21 FY22 FY23 FY24 FY25 1400+ Scientists Generic Development - Biotech Res
Slide 17: Business Updates
Business Updates
Slide 18: India Formulations: Market outperformance led by pillar brands
India Formulations: Market outperformance led by pillar brands and innovation portfolio Branded business continues to deliver healthy growth Strong presence in progressive therapy areas India Formulations Sales (Rs. mn) Therapy-wise Break-up1 59315 53888 48125 49111 40429 Progressive TAs 10% CAGR (F
Slide 19: India Formulations: Rich brand portfolio to drive growth
India Formulations: Rich brand portfolio to drive growth Increasing contribution of Innovation portfolio Growth Strategies • #1 brand in Zydus’ portfolio1 • Provided relief to over 50 Lacs patients since launch Focused brand building initiatives to scale up more • 38% increase in patient base in FY2
Slide 20: Zydus Wellness: A leading consumer wellness player in India
Zydus Wellness: A leading consumer wellness player in India Building strong brand presence over the years Market leadership across brands Consumer Wellness Sales (Rs. mn) Brand Name Mkt Share % Mkt Rank 26810 33.8%* 1* 22338 23017 18409 19788 10% CAGR Facial 7.7%* 5* (FY21-FY25) Cleansing # Scrub 48
Slide 21: Zydus Wellness: Strategic initiatives to drive growth
Zydus Wellness: Strategic initiatives to drive growth Accelerate growth through targeted marketing initiatives such as multi-channel advertising, in-store promotions, strategic pricing, and consumer engagement programs aimed at building brand loyalty Robust GTM strategy aimed at distribution optimiz
Slide 22: US formulations: Focused execution powered by a rich portfolio
US formulations: Focused execution powered by a rich portfolio Strong performance with sustained growth potential Continued investment to build value-centric portfolio US Formulations Sales (Rs. mn) ANDA filings and approvals - 110500 FY25 ^ 74451 86851 15% CAGR 27 24 ^ 63505 58138 (FY21-FY25) $ 856
Slide 23: US formulations: Expanding presence in the specialty space
US formulations: Expanding presence in the specialty space through in-house development as well as inorganic moves 505(b)(2) portfolio – in-house development and partnerships Building rare disease portfolio through acquisitions 9 Molecules in pipeline Molecules acquired so far viz. NULIBRY®, Zokinvy
Slide 24: US formulations: Strategic initiatives to drive growth
US formulations: Strategic initiatives to drive growth Continue delivering strong performance on commercialised products Continue to file 30-35 ANDAs annually and launch new products to address erosion in base portfolio and grow the business Focus on limited competition/ differentiated/ FTF products
Slide 25: International Markets formulations: Leveraging the global portfolio
International Markets (IM) formulations: Leveraging the global portfolio to expand the presence across markets Consistent growth through the years Growth Strategies International Markets Formulations Sales (Rs. mn) Increase the salience of larger brands (known as MDC brands) in emerging market (EM)
Slide 26: JVs and Alliances: Proven track-record of successful partnerships
JVs and Alliances: Proven track-record of successful partnerships • A 50:50 JV with a manufacturing site at Vashi, Navi Mumbai having capabilities to manufacture a range of APIs and intermediates Zydus Takeda • Regulatory compliant mfg. site confirming to both national and international GMP standard
Slide 27: Med-Tech Foray
Med-Tech Foray
Slide 28: Three priority segments in the MedTech space
Zydus has identified three priority segments in the MedTech space to build its global presence Cardiology Nephrology Zydus MedTech – Growth levers Product launches, inorganic opportunities Product pipeline ✓ Building presence in interventional cardiology ✓ Acquired manufacturing facility of Nano ✓ A
Slide 29: Within MedTech, Orthopaedics is large and attractive
Within MedTech, Orthopaedics is large and attractive Orthopaedics market worldwide (in US$ bn) 2024E Segment breakdown Spine 60 17% Others 25% 45 Ortho market 17% Knee 12% 35 Sports Med 15% 14% o/w 31% for Hip knee and hips Trauma segment Robotic-assisted surgery is becoming a competitive necessity,
Slide 30: Amplitude Surgical to act as a platform for Zydus' global MedTech strategy
Amplitude Surgical to act as a platform to execute Zydus’ global MedTech strategy Right fit with Zydus’ strategy of creating an entire ecosystem focused on “Patient Business segment centricity” by offering high quality products and solutions Medical technology is a natural extension Leading position
Slide 31: Amplitude Surgical: Geographic footprint and in-house capabilities
Amplitude Surgical: Geographic footprint and in-house capabilities Value chain positioning Geographic footprint Research and Development International distributors ✓ Run fully in-house with 30 active patents 20+ distribution centres across ✓ Extensive track record of innovation Europe, LATAM, Africa
Slide 32: Agenus: Entry into Global Biologics CDMO business
Agenus: Entry into Global Biologics CDMO business
Slide 33: Agenus: Entry into the CDMO market through two biologics facilities
Agenus: Entry into the high potential CDMO market through the acquisition of two biologics manufacturing facilities in California, the US Deal structure Strategic advantages of the deal US$ 75 mn upfront payment to Agenus for two Immediate access manufacturing facilities each in Emeryville and • Adv
Slide 34: Manufacturing, Supply Chain and Digitalization Initiatives
Manufacturing, Supply Chain and Digitalization Initiatives
Slide 35: Global operations supported by a wide network of manufacturing facilities
Global operations are well supported by a wide network of manufacturing facilities Ahmedabad Human Formulations Multiple dosages (Moraiya) Oral Solids (SEZ I) India Brazil Myanmar Oral Solids (SEZ II) Sikkim Transdermal (SEZ) Formulations Injectables (SEZ) Topicals (Changodar) Oral Solids (Unit I) L
Slide 36: Agile and integrated global supply chain
Agile and integrated global supply chain manages complete value chain from forecasting to demand fulfillment across markets 75+ 4850+ 2600+ 150+ Presence in SKUs being FG (Finished new launches 12+ number of supplied across Goods) batches Dosage Forms per year countries markets demand/ month Key Str
Slide 37: Embracing digital transformation across functions (1/2)
Embracing digital transformation journey across functions to generate greater value for all the stakeholders (1/2) Area: Technical Operations Initiatives Features Benefits • Real-time data analytics dashboard through • Quick and clear insights Data Analytics Software - Tableau integration with diffe
Slide 38: Embracing digital transformation across functions (2/2)
Embracing the digital transformation journey across functions to generate greater value for all the stakeholders (2/2) Area: Supply Chain Initiatives Features Benefits • Platform to bring consensus among • Proactive decision-making to optimize Project PACE multiple stakeholders on planning front pro
Slide 39: Financials
Financials
Slide 40: Key Financial Metrics (1/2)
Key Financial Metrics (1/2) Total Revenues (Rs. mn) GC (Rs. mn) and Gross Margin % 66.7% 62.7% 63.4% 68.1% 72.7% 2,32,415 1,95,474 1,69,035 1,72,374 1,51,099 1,33,192 1,44,035 1,09,273 96,014 95,647 FY21-FY25 FY21-FY25 CAGR: 12.7% CAGR: 15.2% FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 EBITDA
Slide 41: Key Financial Metrics (2/2)
Key Financial Metrics (2/2) Adjusted Net Profit (Rs. mn) Organic Capex (Rs. mn) 47,451 12,140 11,218 38,507 9,579 8,628 7,634 24,097 25,691 21,289 FY21-FY25 CAGR: 18.5% FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 Net Debt/ EBITDA Return on Capital Employed (ROCE) * 24.7% 23.0% 1.03 15.5% 14.3%
Slide 42: ESG and CSR Updates
ESG and CSR Updates
Slide 43: ESG Highlights
ESG Performance Climate Change GS reduction in GHG Intensity by 2030 aw (GHG Emissions) RQ Kr © of target achieved. G Net Carbon Neutral by 2035 RX of renewable energy in the total energy mix Ww Water eg Management G Net Water Neutral by 2028 1 Creation of water recharge structures in progress Achie
Slide 44: Zydus Srishti: the group's CSR program
Zydus Srishti, the group’s CSR program, through five pillars, endeavors to make a difference in the society in sync with Sustainable Development Goals ➢ Driving equitable, quality education ➢ New school built in Changodar near Ahmedabad ➢ Advanced science labs at Zydus School for Excellence SHIKSHA
Slide 45: Well diversified board at the helm of the affairs
Well diversified board at the helm of the affairs Pankaj R. Patel Dr. Sharvil P. Patel Ganesh N. Nayak Mukesh M. Patel Managing Director Executive Director Chairman Non-Executive Director Over 2 decades of experience Associated with the group Over 4 decades of experience An advocate and Internationa
Slide 46: Thank you
Thank you For any queries, please contact Arvind Bothra Arvind.Bothra@zyduslife.com +91-22-62711905 For more information, please visit: www.zyduslife.com Registered Office: www.linkedin.com/company/zyduslife Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi C
Zydus Lifesciences — Investors' Conference, June 25-27, 2025 on 6ix